Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS/MS-based targeted proteomics.

Grangeon A, Clermont V, Barama A, Gaudette F, Turgeon J, Michaud V.

J Pharm Biomed Anal. 2019 Sep 5;173:96-107. doi: 10.1016/j.jpba.2019.05.006. Epub 2019 May 4.

PMID:
31125949
2.

Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes.

Gravel S, Chiasson JL, Gaudette F, Turgeon J, Michaud V.

Clin Pharmacol Ther. 2019 Apr 19. doi: 10.1002/cpt.1472. [Epub ahead of print]

PMID:
31002385
3.

Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat.

Frouni I, Kwan C, Bédard D, Belliveau S, Bourgeois-Cayer É, Gaudette F, Beaudry F, Hamadjida A, Huot P.

Exp Brain Res. 2019 Jan;237(1):29-36. doi: 10.1007/s00221-018-5390-4. Epub 2018 Oct 8.

PMID:
30298296
4.

Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset.

Gaudette F, Hamadjida A, Bédard D, Nuara SG, Gourdon JC, Michaud V, Beaudry F, Huot P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:1-7. doi: 10.1016/j.jchromb.2018.06.036. Epub 2018 Jun 19.

PMID:
29980099
5.

The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset.

Hamadjida A, Nuara SG, Bédard D, Gaudette F, Beaudry F, Gourdon JC, Huot P.

Neuropharmacology. 2018 Sep 1;139:61-67. doi: 10.1016/j.neuropharm.2018.06.038. Epub 2018 Jun 30.

PMID:
29969592
6.

Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes.

Huguet J, Gaudette F, Michaud V, Turgeon J.

Xenobiotica. 2019 Feb;49(2):187-199. doi: 10.1080/00498254.2018.1438684. Epub 2018 Mar 8.

PMID:
29448869
7.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma.

Gaudette F, Hamadjida A, Bédard D, Nuara SG, Beaudry F, Huot P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:392-398. doi: 10.1016/j.jchromb.2017.07.007. Epub 2017 Jul 15.

PMID:
28802219
8.

Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human.

Grangeon A, Gravel S, Gaudette F, Turgeon J, Michaud V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:144-158. doi: 10.1016/j.jchromb.2016.12.006. Epub 2016 Dec 6.

PMID:
27978469
9.

No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.

Huguet J, Lu J, Gaudette F, Chiasson JL, Hamet P, Michaud V, Turgeon J.

Eur J Clin Pharmacol. 2016 Aug;72(8):925-31. doi: 10.1007/s00228-016-2065-6. Epub 2016 May 5.

PMID:
27146814
10.

Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry.

Gaudette F, Sirhan-Daneau A, St-Onge M, Turgeon J, Michaud V.

J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:174-180. doi: 10.1016/j.jchromb.2015.11.035. Epub 2015 Nov 23.

PMID:
26655109
11.

Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.

Gaudette F, Benito J, Steagall P, Beaudry F.

Biomed Chromatogr. 2015 Nov;29(11):1724-30. doi: 10.1002/bmc.3485. Epub 2015 May 12.

PMID:
25963121
12.

Effects of β-blockers and tricyclic antidepressants on the activity of human organic anion transporting polypeptide 1A2 (OATP1A2).

Lu J, Michaud V, Moya LG, Gaudette F, Leung YH, Turgeon J.

J Pharmacol Exp Ther. 2015 Mar;352(3):552-8. doi: 10.1124/jpet.114.219287. Epub 2015 Jan 6.

PMID:
25563901
13.

Identification of a Novel Series of Potent TrkA Receptor Tyrosine Kinase Inhibitors.

Raeppel SL, Gaudette F, Nguyen H, Beaulieu N, Wang J, Maroun C, Besterman JM, Vaisburg A.

Int J Med Chem. 2012;2012:412614. doi: 10.1155/2012/412614. Epub 2012 May 2.

14.

Identification of a novel series of potent RON receptor tyrosine kinase inhibitors.

Raeppel S, Gaudette F, Mannion M, Claridge S, Saavedra O, Isakovic L, Déziel R, Beaulieu N, Beaulieu C, Dupont I, Nguyen H, Wang J, Macleod AR, Maroun C, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2010 May 1;20(9):2745-9. doi: 10.1016/j.bmcl.2010.03.073. Epub 2010 Mar 19.

PMID:
20363625
15.

Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.

Gaudette F, Raeppel S, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Macleod AR, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):848-52. doi: 10.1016/j.bmcl.2009.12.099. Epub 2010 Jan 4.

PMID:
20071170
16.

N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Saavedra O, Claridge S, Zhan L, Raeppel F, Granger MC, Raeppel S, Mannion M, Gaudette F, Zhou N, Isakovic L, Bernstein N, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Wang J, Macleod AR, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2009 Dec 15;19(24):6836-9. doi: 10.1016/j.bmcl.2009.10.095. Epub 2009 Oct 25.

PMID:
19896842
17.

N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Mannion M, Raeppel S, Claridge S, Zhou N, Saavedra O, Isakovic L, Zhan L, Gaudette F, Raeppel F, Déziel R, Beaulieu N, Nguyen H, Chute I, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman JM, Vaisburg A.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6552-6. doi: 10.1016/j.bmcl.2009.10.040. Epub 2009 Oct 13.

PMID:
19854051
18.

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.

Raeppel S, Claridge S, Saavedra O, Gaudette F, Zhan L, Mannion M, Zhou N, Raeppel F, Granger MC, Isakovic L, Déziel R, Nguyen H, Beaulieu N, Beaulieu C, Dupont I, Robert MF, Lefebvre S, Dubay M, Rahil J, Wang J, Ste-Croix H, Robert Macleod A, Besterman J, Vaisburg A.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1323-8. doi: 10.1016/j.bmcl.2009.01.068. Epub 2009 Jan 27.

PMID:
19211249
19.

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).

Raeppel S, Zhou N, Gaudette F, Leit S, Paquin I, Larouche G, Moradei O, Fréchette S, Isakovic L, Delorme D, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Rahil J, Wang J, Besterman JM, Murakami K, Li Z, Vaisburg A.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):644-9. doi: 10.1016/j.bmcl.2008.12.048. Epub 2008 Dec 24.

PMID:
19114304
20.

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Zhou N, Moradei O, Raeppel S, Leit S, Frechette S, Gaudette F, Paquin I, Bernstein N, Bouchain G, Vaisburg A, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Lu A, Rahil J, MacLeod AR, Li Z, Besterman JM, Delorme D.

J Med Chem. 2008 Jul 24;51(14):4072-5. doi: 10.1021/jm800251w. Epub 2008 Jun 21.

PMID:
18570366
21.

4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.

Fréchette S, Leit S, Woo SH, Lapointe G, Jeannotte G, Moradei O, Paquin I, Bouchain G, Raeppel S, Gaudette F, Zhou N, Vaisburg A, Fournel M, Yan PT, Trachy-Bourget MC, Kalita A, Robert MF, Lu A, Rahil J, Robert Macleod A, Besterman JM, Li Z, Delorme D.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1502-6. doi: 10.1016/j.bmcl.2007.12.057. Epub 2007 Dec 25.

PMID:
18207391
22.

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.

Paquin I, Raeppel S, Leit S, Gaudette F, Zhou N, Moradei O, Saavedra O, Bernstein N, Raeppel F, Bouchain G, Fréchette S, Woo SH, Vaisburg A, Fournel M, Kalita A, Robert MF, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Rahil J, MacLeod AR, Besterman JM, Li Z, Delorme D.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1067-71. Epub 2007 Dec 10.

PMID:
18160287
23.

N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors.

Vaisburg A, Paquin I, Bernstein N, Frechette S, Gaudette F, Leit S, Moradei O, Raeppel S, Zhou N, Bouchain G, Woo SH, Jin Z, Gillespie J, Wang J, Fournel M, Yan PT, Trachy-Bourget MC, Robert MF, Lu A, Yuk J, Rahil J, Macleod AR, Besterman JM, Li Z, Delorme D.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33. Epub 2007 Oct 18.

PMID:
17977726
24.

Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.

Moradei O, Leit S, Zhou N, Fréchette S, Paquin I, Raeppel S, Gaudette F, Bouchain G, Woo SH, Vaisburg A, Fournel M, Kalita A, Lu A, Trachy-Bourget MC, Yan PT, Liu J, Li Z, Rahil J, MacLeod AR, Besterman JM, Delorme D.

Bioorg Med Chem Lett. 2006 Aug 1;16(15):4048-52. Epub 2006 May 18.

PMID:
16713259
25.

Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.

Oguma T, Cicci D, Gaudette F, Gauthier-Dubois G, Guilbaud R, Atsumi R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Apr 25;818(2):249-56.

PMID:
15734166

Supplemental Content

Loading ...
Support Center